StreetAlpha.app
Home › Stocks › CRSP

CRISPR Therapeutics AG (CRSP)

Healthcare
$40.15
▼ −0.54%
LAST CLOSE · NOV 17

CRISPR Therapeutics develops gene editing medicines, including CASGEVY, an approved therapy for sickle cell disease and beta thalassemia. It last closed at $40.15 on Nov 17, down 0.54% on the day. CRSP reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 5 analysts is $74.80 (+86.3% from the last close), with a high of $90.00 and a low of $52.00. Analyst consensus is Buy, based on the latest ratings from 5 firms (3 buy, 2 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $1.8M, the largest $1.1M.

AI Auto Pilots
Is CRSP in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$25.2M
−34.3% vs a year ago
Net income
−$456.1M
−1812.1% margin
EPS (diluted)
−$4.73
Free cash flow
−$376.7M
−1496.6% margin
Valuation
Market cap
$3.9B
97.0M shares
P/E
–
No P/E while losing money
Price to sales
154.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$192.0M
At Sep 30
Debt
$586.9M
At Sep 30
Shareholder equity
$1.6B
Shares outstanding
97.0M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $915.0M$915.0MFY2021FY2022: $1.2M$1.2MFY2022FY2023: $371.2M$371.2MFY2023FY2024: $37.3M$37.3MFY2024FY2025: $3.5M$3.5MFY2025

From CRSP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.

Next report
Feb 11
2027 · Time not announced
Consensus EPS forecast
-$1.17
$11.3M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
5firms
3 Buy2 Hold0 Sell
Each firm's latest rating on CRSP in the past 90 days
Average 12-month target
$74.80
▲ 86.3% upside

Based on 5 analysts who set a price target on CRSP in the past 90 days. The average target is $74.80, with a high of $90.00 and a low of $52.00, compared with the last close of $40.15.

$36$55$75$94PAST 13 TRADING DAYS12-MONTH TARGETSHIGH $90AVG $74.80LOW $52Jun 4LAST CLOSE+12 MO$36$55$75$94PAST 13 DAYSTARGETSHIGH $90AVG $74.80LOW $52Jun 4LAST CLOSE+12 MO
Highest target$90.00
Average target$74.80
Lowest target$52.00
Latest rating changes
CitigroupTarget raised
Nov 4Buy$88 → $90
Wells FargoMaintained
Nov 4Hold$70
NeedhamReiterated
Nov 3Buy$82
UBSInitiated
Oct 15Hold$52
CitizensReiterated
Aug 31Buy$80
DateFirmActionRatingPrice target
Nov 4CitigroupTarget raisedBuy$88 → $90
Nov 4Wells FargoMaintainedHold$70
Nov 3NeedhamReiteratedBuy$82
Oct 15UBSInitiatedHold$52
Aug 31CitizensReiteratedBuy$80
Loading…

Technical Analysis

CRSP · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 20% below its 20 day and 28% below its 50 day average. It is 31% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $39.80, and the nearest resistance the Pivot at $40.37.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityNormal, 6.4%/day
Key levels
$63.4552 week high+58.0%
$55.02Swing high (Aug 12)+37.0%
$52.62100 day average+31.1%
$52.42200 day average+30.6%
$51.4950 day average+28.2%
$48.3420 day average+20.4%
$40.95Pivot R1+2.0%
$40.37Pivot+0.5%
$40.15Last close
$39.8052 week low−0.9%
$39.57Pivot S1−1.4%
Indicators
RSI (14)28.90Oversold below 30Oversold
MACD-2.84Below its signal lineBearish
Stochastic2.9Near the bottom of its rangeOversold
ADX (14)19.1No clear trend
Williams %R-97.8Oversold below −80, overbought above −20Oversold
CCI (20)-168.9Oversold below −100, overbought above 100Oversold
Rate of change−19.7%Change over 10 sessionsBearish
ATR (14)$2.56Typical daily range, 6.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CRSP

What happened before

See how CRSP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CRSP usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CRSP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in CRSP in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$1.8M
Largest print
$1.1M
Loading…

CRSP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲233 buying vs 201 selling
  • ●Held by funds +0.1 pts
  • ▼Funds holding -21
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding504525−4.0%
In funds' top 10660.0%
Held by funds79.0%78.8%+0.1 pts
New / increased57 / 17674 / 156+1.3%
Reduced / sold out136 / 65141 / 47+6.9%
Put/call ratio0.680.75−9.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CRSP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRSP is in one of them and how their past CRSP trades turned out.

CRSP in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CRSP in an article yet. Here's the latest on the wider market.

CRSP Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed May 17
Who traded CRSP · since 2017
Latest 5 filings of 9
$1K – $15KTraded Apr 4, 2025Filed May 17, 2025
$1K – $15KTraded Feb 24, 2025Filed Mar 22, 2025
$50K – $100KTraded Sep 20, 2021Filed Oct 5, 2021
$50K – $100KTraded Jun 3, 2021Filed Sep 23, 2021
$1K – $15KTraded Jan 21, 2021Filed Feb 19, 2021
PersonTypeAmountTradedFiledDelay
Robert KennedyExecutive branchSell$1K – $15KApr 4, 2025May 17, 202543 d
Ashley MoodyR · FLSell$1K – $15KFeb 24, 2025Mar 22, 202526 d
Tom SuozziD · NYSell$50K – $100KSep 20, 2021Oct 5, 202115 d
Tom SuozziD · NYBuy$50K – $100KJun 3, 2021Sep 23, 2021112 d
Marjorie Taylor GreeneR · GABuy$1K – $15KJan 21, 2021Feb 19, 202129 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About CRISPR Therapeutics AG

CRISPR Therapeutics is a biopharmaceutical company based in Zug, Switzerland, that develops medicines using CRISPR gene editing technology. Its approved therapy, CASGEVY, is co-developed and co-commercialized with Vertex and treats eligible patients with sickle cell disease or beta thalassemia. The company's pipeline also includes gene editing treatments for liver diseases, siRNA medicines for cardiovascular and clotting conditions, cell therapies for autoimmune diseases and cancer, and a cell-based treatment for type 1 diabetes. Its medicines target patients with serious diseases, and partners include Vertex and Eli Lilly.

Headquarters
Zug
Founded
2013